→
Edwards Lifesciences Corp
Edwards Lifesciences Corp (EW) currently trades at $81.71, reflecting a market cap of $47.46B, but faces challenges with a significant EPS growth decline of -73.77% despite a revenue growth of 6.00% year-over-year. The stock's P/E ratio stands at 44.52, which is high compared to the industry average, indicating overvaluation risks, especially after missing Q4 2025 earnings estimates by 12.05%.
Given the mixed performance and high valuation, maintaining a neutral stance on Edwards Lifesciences is prudent at this time.
Evercore ISI Group Maintains Outperform on Edwards Lifesciences, Lowers Price Target to $92
2026-04-06
Tired of AI and Oil? Buy the Robot.
2026-04-08